Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
Japan’s first Avastin (bevacizumab) biosimilar made its debut on December 9, with Pfizer Japan pitting the product against Chugai Pharmaceutical’s heavyweight cancer drug - albeit in a limited indication of colorectal cancer. Bevacizumab BS for IV Infusion 100 mg/400 mg…
To read the full story
Related Article
- Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
August 29, 2023
- Pfizer Seeks Breast Cancer Use for Avastin Biosimilar
November 24, 2022
- Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
- Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
December 20, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- Japan Approves 1st Avastin Biosimilar
June 19, 2019
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Nippon Kayaku to Buy Fuji Yakuhin’s Injectable Plant in Japan
April 2, 2026
- Teijin Slashes FY2025 Forecast on Pharma Impairment
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…